About ERO1-like protein alpha
ERO1-like protein alpha (ERO1A) is a protein
from Homo sapiens identified by UniProt accession
Q96HE7, 468 residues long.
MolForge cross-references it against 0 known binders and
123 disease associations.
Target properties
| Protein name | ERO1-like protein alpha |
| UniProt accession | Q96HE7 |
| Gene | ERO1A |
| Organism | Homo sapiens |
| Length | 468 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (123)
Diseases linked to this target (Open Targets).
- heel bone mineral density · score 0.37
- urinary metabolite measurement · score 0.24
- sitting height measurement · score 0.22
- endometrial cancer · score 0.18
- breast adenocarcinoma · score 0.18
- low grade glioma · score 0.17
- protein measurement · score 0.15
- neoplasm · score 0.11
- lung adenocarcinoma · score 0.10
- non-small cell lung carcinoma · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96HE7-F1 | alphafold | PREDICTED | 75.65 | — |
Amino-acid sequence (468 residues)
MGRGWGFLFG LLGAVWLLSS GHGEEQPPET AAQRCFCQVS GYLDDCTCDV ETIDRFNNYR LFPRLQKLLE SDYFRYYKVN LKRPCPFWND ISQCGRRDCA VKPCQSDEVP DGIKSASYKY SEEANNLIEE CEQAERLGAV DESLSEETQK AVLQWTKHDD SSDNFCEADD IQSPEAEYVD LLLNPERYTG YKGPDAWKIW NVIYEENCFK PQTIKRPLNP LASGQGTSEE NTFYSWLEGL CVEKRAFYRL ISGLHASINV HLSARYLLQE TWLEKKWGHN ITEFQQRFDG ILTEGEGPRR LKNLYFLYLI ELRALSKVLP FFERPDFQLF TGNKIQDEEN KMLLLEILHE IKSFPLHFDE NSFFAGDKKE AHKLKEDFRL HFRNISRIMD CVGCFKCRLW GKLQTQGLGT ALKILFSEKL IANMPESGPS YEFHLTRQEI VSLFNAFGRI STSVKELENF RNLLQNIH
Explore ERO1-like protein alpha with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets